The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
暂无分享,去创建一个
Gordon B Mills | Lynda Chin | Michael A Davies | L. Chin | G. Mills | K. Tsai | G. Genovese | Tony Gutschner | I. Watson | Liren Li | Guocan Wang | Katherine Stemke-Hale | Ian R Watson | Guocan Wang | Tony Gutschner | Kenneth Y Tsai | Giannicola Genovese | Liren Li | Peter K Cabeceiras | Mozhdeh Mahdavi | Zhuangna Fang | James M Tepper | Z. Fang | Peter K. Cabeceiras | M. Davies | K. Stemke‐Hale | James Tepper | M. Mahdavi
[1] G. Bokoch,et al. Characterization of Rac and Cdc42 Activation in Chemoattractant-stimulated Human Neutrophils Using a Novel Assay for Active GTPases* , 1999, The Journal of Biological Chemistry.
[2] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[3] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[4] J. Sosman,et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. , 2012, Cancer discovery.
[5] P. Tamayo,et al. Integrative functional genomics identifies RINT1 as a novel GBM oncogene , 2012, Neuro-oncology.
[6] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[7] D. Schadendorf,et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.
[8] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[9] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[10] Young Lim Choi,et al. Transforming mutations of RAC guanosine triphosphatases in human cancers , 2013, Proceedings of the National Academy of Sciences.
[11] R. Sullivan,et al. Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.
[12] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[13] Kate Owen,et al. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2016, eLife.
[14] Y. Matsuo,et al. False leukemia–lymphoma cell lines: an update on over 500 cell lines , 2003, Leukemia.
[15] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[16] Antoni Ribas,et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.
[17] Alan Hall,et al. Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.
[18] L. Garraway,et al. C-RAF mutations confer resistance to RAF inhibitors. , 2013, Cancer research.
[19] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[20] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[21] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[22] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[23] L. Chin,et al. Melanoma: from mutations to medicine. , 2012, Genes & development.
[24] Rajiv Narayan,et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.
[25] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[26] A. McKenna,et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.
[27] Ultan McDermott,et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.
[28] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[29] M. Kazanietz,et al. Rac signaling in breast cancer: a tale of GEFs and GAPs. , 2012, Cellular signalling.
[30] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[31] Matthew J. Davis,et al. RAC1P29S is a spontaneously activating cancer-associated GTPase , 2013, Proceedings of the National Academy of Sciences.
[32] S. Larson,et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. , 2011, The Journal of clinical investigation.
[33] V. Sondak,et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.
[34] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[35] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[36] A. Bucheit,et al. Emerging insights into resistance to BRAF inhibitors in melanoma. , 2014, Biochemical pharmacology.
[37] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.